Acticor Biotech technology
Acticor Biotech’s product is a therapeutic antibody (Fab) targeting glycoprotein VI, with a safety profile suitable for clinical use.
acticor-biotech.comCrawled Nov 7, 2026
Acticor Biotech’s product is a therapeutic antibody (Fab) targeting glycoprotein VI, with a safety profile suitable for clinical use.
Acticor Biotech’s product is an antibody targeting platelet glycoprotein VI (GPVI).
Research describes ACT017, a humanized Fab blocking glycoprotein VI without bleeding risks, published in *mAbs*.
An ischemic stroke, or cerebral attack, causes sudden neurological deficits. The page features an interview with Professor Amarenco.
Immobilized fibrinogen activates human platelets through glycoprotein VI, as shown in *Haematologica* (2018).
Research in *International Journal of Stroke* (2016) explores glycoprotein VI’s role beyond antiplatelet treatments in ischemic stroke.
A 2015 *Journal of Thrombosis and Haemostasis* article examines antiplatelet drug targets for stroke treatments.
Platelet glycoprotein VI binds to fibrin and promotes thrombin generation, according to research published in *Blood* (2015).
Acticor Biotech secured an additional 7 million euros in November 2019, bringing its second funding round to 22.3 million euros.
Acticor Biotech raised 10 million euros in 2018 to advance to Phase II trials.
Members and observers
Gilles Avenard, MD, serves as CEO and board member for multiple biotech firms, including BioAlliance Pharma and ONXEO.
Acticor Biotech team presentation
Acticor Biotech is an Inserm spin-off founded in November 2013, based at Inserm U1148 in Hôpital Bichat, Paris.
Acticor Biotech opens its capital to fund development of an innovative, effective, and safe emergency treatment for ischemic stroke.
Investors and partners
Acticor Biotech is headquartered at Inserm U1148, Hôpital Bichat, Paris, France.